jublia
Valeant CEO cuts outlook for ‘distracted’ company, shares plunge
June 8, 2016 by elegant · Leave a Comment
Valeant Pharmaceuticals International Inc slashed its 2016 forecasts on Tuesday, as its new chief executive said he would focus on rebuilding the reputation of a “distracted organization” with a debt-loaded balance sheet. The maker of toenail fungus cream Jublia and anti-depressant drug Wellbutrin, which has faced intense scrutiny for business and accounting practices, missed first-quarter profit estimates on weakness in its dermatology business.
More:
Valeant CEO cuts outlook for ‘distracted’ company, shares plunge